Logo

Zydus Lifesciences Share Price

NSE: ZYDUSLIFE
|
Pharmaceuticals
₹ 1,140.60
+₹40.80 (3.71%)
1D
Last updated 03 Jul, 2026, 15:58 IST

Zydus Lifesciences Share Price Today

As of 5 Jul 2026, Zydus Lifesciences share price is ₹1,140.60. The stock opened at ₹1,105.00, compared to its previous close of ₹1,099.80. During today's trading session, Zydus Lifesciences share price moved in the range of ₹1,104.10 to ₹1,142.90, with an average price of ₹1,123.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹835.50 and a high of ₹1,142.90. On the performance front, Zydus Lifesciences share price has increased by 24.40% over the last six months and is up 14.13% on a year-on-year basis.

₹1,104.10
3.71% up today
₹1,142.90
1D LOW
1D HIGH

Zydus Lifesciences Returns Calculator

Open
₹1,105.00
High
₹1,142.90
Low
₹1,104.10
Prev. close
₹1,099.80
Circuit
L
H
₹1,026.60
₹1,254.60
52-week
L
H
₹835.50
₹1,142.90

Zydus Lifesciences Shareholder Returns

Zydus Lifesciences Share Price History

Mkt Cap Cr
1,10,651.00
P/E
21.60
P/B
4.08
ROE
18.59%
D/E
0.31
ROCE
17.35%
Div. Yield
0.09%
EPS(TTM)
35.38
Turnover
0.39
EV/EBITDA
14.49
Net Margin
0.00%
Op. Margin
0.00%
ROA
9.59%
Quick Ratio
0.00
Curr. Ratio
6.79
Based on fundamentals, this stock's
Step 2 of 5
Performance
Poor
Zydus Lifesci. has underperformed the market
Step 3 of 5
Valuation
Fairly Valued
Zydus Lifesci. appears to be fairly valued compared to its peers
Step 5 of 5
Earnings
Excellent
Zydus Lifesci. revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,49,048.0039.025.3713.74%0.6117.33%93.240.85%0.5610.90
Divis Laboratories1,77,179.0069.0010.5715.32%0.0019.56%629.490.45%0.5898.19
Torrent Pharmaceuticals1,57,804.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,17,642.0025.472.8711.79%0.0015.66%2.891.06%0.4943.52
Dr. Reddy's Laboratories1,12,368.0027.032.9711.07%0.1812.54%375.780.59%0.6338.68
Lupin1,09,676.0020.484.8923.76%0.0424.88%659.050.75%0.61129.18
Mankind Pharma1,02,729.0053.006.3011.74%0.3413.13%397.020.04%0.5449.37
Aurobindo Pharma90,608.0025.872.399.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs82,398.9060.2610.1018.21%0.4516.70%10.190.20%0.9713.72
Biocon68,267.90185.351.991.14%0.043.64%168.190.12%0.090.27

Zydus Lifesciences Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹23,241.50₹19,547.40₹17,237.40₹15,109.90
Other Income₹269.50₹284.10₹186.60₹224.70
Total Revenue₹23,511.00₹19,831.50₹17,424.00₹15,334.60
Total Expenses₹17,264.70₹15,008.40₹14,230.10₹12,609.20
Profit Before Tax₹6,026.70₹4,808.90₹2,589.70₹2,838.10
Tax₹1,411.90₹977.50₹587.80₹511.70
Profit After Tax₹4,614.80₹3,831.40₹2,001.90₹2,326.40
EPS - Basic₹44.97₹38.14₹19.30₹43.83
EPS - Diluted₹44.97₹38.14₹19.30₹43.83

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹6,026.70₹4,838.10₹2,582.70₹5,232.30
Income before WC changes₹7,047.10₹5,384.80₹3,516.60₹3,130.20
Change in Assets₹921.80-₹893.40-₹261.90-₹425.90
Change in Liabilities₹609.70₹22.30₹26.10₹74.40
Change in WC₹1,531.50-₹871.10-₹235.80-₹351.50
Cash flow from Operations₹6,776.70₹3,227.90₹2,688.80₹2,104.10
Cash flow from Investing-₹8,372.30-₹1,475.20₹1,171.20₹1,154.40
Cash flow from Financing₹2,014.20-₹1,810.40-₹4,400.40-₹868.30
Total Cash Flow₹418.60-₹57.70-₹540.40₹2,390.20
Cash (Start of the year)₹413.00₹487.80₹1,106.90₹1,087.20
Cash (End of the year)₹826.80₹413.00₹573.10₹3,460.10

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹20,155.60₹17,861.00₹15,748.20₹15,700.20
Current Assets₹17,046.10₹11,419.80₹10,008.20₹12,095.20
Total Assets₹37,201.70₹29,280.80₹25,756.40₹27,795.40
Current Liabilities₹9,041.60₹5,339.70₹5,526.70₹7,826.80
Net Current Asset₹8,004.50₹6,080.10₹4,481.50₹4,268.40
Non-Current Liabilities₹1,801.70₹1,839.50₹541.40₹914.80
Equity Capital₹26,358.40₹22,101.60₹19,688.30₹19,053.80
Total Equity & Liabilities₹37,201.70₹29,280.80₹25,756.40₹27,795.40

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹15,116.30₹10,818.70₹8,731.60₹7,981.90
Other Income₹696.20₹1,084.80₹548.40₹178.70
Total Revenue₹15,812.50₹11,903.50₹9,280.00₹8,160.60
Total Expenses₹8,367.80₹7,655.10₹7,044.00₹6,677.40
Profit Before Tax₹7,444.70₹4,239.80₹2,032.20₹1,163.90
Tax₹1,669.80₹798.30₹503.00₹306.00
Profit After Tax₹5,774.90₹3,441.50₹1,529.20₹857.90
EPS - Basic₹57.39₹34.01₹15.06₹8.38
EPS - Diluted₹57.39₹34.01₹15.06₹8.38

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹7,444.70₹4,239.80₹2,032.20₹1,163.90
Income before WC changes₹7,769.80₹4,090.80₹2,507.30₹1,989.60
Change in Assets-₹3,467.20-₹1,272.50-₹1,070.60-₹354.30
Change in Liabilities₹159.50₹79.70₹34.70-₹54.60
Change in WC-₹3,307.70-₹1,192.80-₹1,035.90-₹408.90
Cash flow from Operations₹3,114.00₹2,000.30₹1,078.20₹1,310.70
Cash flow from Investing-₹4,503.60-₹1,831.80-₹1,959.30₹768.20
Cash flow from Financing₹1,384.50-₹300.80₹827.00-₹1,709.80
Total Cash Flow-₹5.10-₹132.30-₹54.10₹369.10
Cash (Start of the year)₹108.10₹240.40₹294.50₹154.00
Cash (End of the year)₹103.00₹108.10₹240.40₹523.10

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹17,002.20₹16,173.50₹13,405.40₹10,902.60
Current Assets₹15,314.70₹7,911.30₹7,158.20₹6,837.40
Total Assets₹32,316.90₹24,084.80₹20,563.60₹17,740.00
Current Liabilities₹7,851.40₹2,541.40₹2,790.10₹4,027.90
Net Current Asset₹7,463.30₹5,369.90₹4,368.10₹2,809.50
Non-Current Liabilities₹3,275.40₹5,826.90₹4,134.10₹471.60
Equity Capital₹21,190.10₹15,716.50₹13,639.40₹13,240.50
Total Equity & Liabilities₹32,316.90₹24,084.80₹20,563.60₹17,740.00
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
1140.6
2220
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 2220
Buy orders: 0%
Sell orders: 100%
Bearish
4
Neutral
3
Bullish
1
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
66.88
Neutral
ATR (14)
24.84
Neutral
STOCH(9,6)
97.06
Bearish
STOCH RSI (14)
100
Bearish
ADX(9)
36.07
Bearish
UO(9)
48.05
Neutral
ROC(12)
5.74
Bullish
WillR(14)
-2.58
Bearish
Period
Simple value
Exponential vaue
5D
1116.7
1116.96
10D
1105.27
1108.15
20D
1097.32
1093.56
50D
1032.8
1045.62
100D
968.48
1001.61

About Zydus Lifesciences

Zydus Lifesciences logo
ISIN
INE010B01027
Sector Market Cap
₹ 1,10,651 Cr

Zydus Lifesciences Limited is an India-based life-sciences company with positions across pharmaceuticals and consumer wellness, supported by a MedTech franchise and a global footprint across United States, India and other international markets. Its pharmaceutical business includes integrated pharmaceutical operations with business encompassing the entire value chain in research, development, production, marketing and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, human formulations, and animal health and veterinary. Its consumer products business includes development, production, marketing and distribution of differentiated health and wellness products. It provides biologicals manufacturing sites offering contract development and manufacturing organization services to biopharmaceutical companies globally. Its focused therapy areas include cardiology, anti-diabetes, super specialty areas of oncology and nephrology, and others.

Zydus Lifesciences Financial Highlights

  • Revenue: Zydus Lifesciences reported revenue of ₹27,657.90 crore in FY26 vs ₹23,511.00 crore in FY25. It showed an increase of 17.64% on a yearly basis.
  • Operating Profit: Zydus Lifesciences reported an operating profit of ₹6,621.10 crore in FY26 vs ₹6,026.70 crore in FY25. It showed an increase of 9.86% on a year-on-year basis.
  • Net Profit: Zydus Lifesciences reported a net profit of ₹5,026.40 crore in FY26 vs ₹4,614.80 crore in FY25. It showed an increase of 8.92% on a yearly basis.

Zydus Lifesciences Quarterly Result Highlights

  • Zydus Lifesciences reported revenue of ₹7,721.20 crore in Mar 2026, compared with ₹6,975.90 crore in Dec 2025, representing an increase of 10.68% on a quarter-on-quarter (QoQ) basis.
  • Zydus Lifesciences reported an operating profit of ₹1,659.70 crore in Mar 2026, compared with ₹1,353.40 crore in Dec 2025, representing an increase of 22.63% on a quarter-on-quarter (QoQ) basis.
  • Zydus Lifesciences reported a profit of ₹1,341.30 crore in Mar 2026, compared with ₹965.10 crore in Dec 2025, reflecting an increase of 38.98% on a QoQ basis.
  • The earnings per share (EPS) of Zydus Lifesciences stood at ₹44.97 during Mar 2026.
Know more
Promoters
75.01%
FII
6.89%
Other DII
6.27%
Retail and other
6.90%
Mutual funds
4.92%
Foreign institutions - FII
Compare against other stocks
Zydus Lifesciences logo
Zydus Lifesciences
Pharmaceuticals
Add Stock
Add Another

FAQs on Zydus Lifesciences Share Price